Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

From cancer medication to antibiotic

16.12.2019

Researchers at the HZI and the TU Munich repurpose drug as MRSA treatment

The bacterium Staphylococcus aureus can be part of the normal bacterial population inhabiting our body, but can also cause serious infections. This bacterium has often developed resistance to standard antibiotics or even multi-resistance to several antibiotics such as methicillin-resistant Staphylococcus aureus (MRSA). Particularly in hospitals, MRSA is often the cause of severe and difficult-to-treat infections.


Scanning electron microscope image of intact MRSA (blue), vesicle formation induced by PK150 (green) and MRSA destroyed by PK150 (red).

HZI/Manfred Rohde

Therefore, there is an urgent need for new drugs that can effectively treat MRSA infections. In order to shorten the lengthy and expensive development process, scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Technical University of Munich (TUM) have used an innovative approach to antibiotic development.

The researchers used chemical synthesis to significantly improve the antimicrobial properties of an approved cancer medicament that also has a moderate killing activity on MRSA. The resulting molecule, named PK150, is highly effective against MRSA infections without the development of resistance. The results are published in the journal Nature Chemistry.

Antibiotic resistance occurs naturally in bacteria as a mechanism to defend themselves and survive in the course of evolution. However, due to the large-scale and often erroneous use of antibiotic drugs, antibiotic resistant pathogens are becoming more widespread.

Infections with multi-resistant pathogens that can withstand several types of antibiotics are frequently difficult to treat. Staphylococcal strains that are resistant to several antibiotics including methicillin (MRSA) are now common, and infections caused by these multi-resistant staphylococci are also on the rise.

“The development of new antibiotics by the pharmaceutical industry has been slowed down several years ago and, therefore, cannot cope with the spread of antibiotic resistance. We urgently need innovative approaches to address the need for new infection treatments that do not immediately lead to development of resistance,” says Prof Eva Medina, head of the research group “Infection Immunology” at the HZI.

Testing already existing and approved human drugs for a potential anti-microbial effect on bacteria is a promising strategy. “Our focus was on a class of human proteins, kinases, for which there are already many inhibitors,” says the leader of the study, Prof Stephan Sieber, Professor for Organic Chemistry at the TUM and scientifically associated with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), one of the HZI sites in cooperation with the Saarland University. Sorafenib, a cancer drug that is effective against MRSA, was systematically chemically modified by the researchers to increase its antibiotic effect. In this way, they developed the molecule PK150, which is ten times more effective against MRSA than the original substance.

The potent new drug acts against multiple unconventional target structures in Staphylococcus aureus. Two targets were investigated more closely: PK150 inhibits an essential protein of the bacterial energy metabolism and also acts on the cell wall.

In contrast to well-known antibiotics such as penicillin and methicillin, which interfere with the formation of the cell wall, PK150 acts indirectly. It disrupts the protein secretion of the bacteria, causing the bacteria to release more proteins, which control the thickness of the cell wall, causing cells burst. “Due to the chemical changes in the molecule, PK150 no longer binds to human kinases, but instead acts very specifically against bacterial targets,” says Sieber.

Medina and Dr Katharina Rox, pharmacologist in the department “Chemical Biology” at the HZI, showed that PK150 exhibits beneficial pharmacological properties. For example, it could be given as a tablet and is stable in the body for several hours. In an infection model in mice (in vivo), PK150 was effective against Staphylococcus aureus in different tissues.

While staphylococci can rapidly develop resistance to other antibiotics, the researchers did not observe any resistance to PK150. Prof Dietmar Pieper, head of the research group “Microbial Interactions and Processes” at the HZI, explains that the simultaneous development of resistance at several targets is much more difficult for bacteria.

“MRSA infections are frequently chronic, because the bacteria can fall into a resting state. PK150 also kills these long-lasting persister cells as well as those bacteria, which are protected in biofilms. PK150 has many properties that make it a promising antibiotic candidate,” says Sieber. In order to move into the clinical development phase, PK150 is currently being optimised by aBACTER, a project funded by a VIP+ grant of the Federal Ministry of Education and Research.

After the embargo you can find this press release on our homepage: https://www.helmholtz-hzi.de/en/news-events/news/

Images are already available on the website of the Technical University of Munich: https://mediatum.ub.tum.de/1524870

The Helmholtz Centre for Infection Research:
Scientists at the Helmholtz Centre for Infection Research (HZI) investigate the mechanisms of infections and of the defences against infections. What is it that makes bacteria or viruses pathogenic? The answer to this question is expected to be key to the development of new medications and vaccines. The HZI is a member of the German Center for Infection Research (DZIF). http://www.helmholtz-hzi.de/en

Contact:
Susanne Thiele, Press Officer
susanne.thiele@helmholtz-hzi.de
Dr Andreas Fischer, Editor
andreas.fischer@helmholtz-hzi.de

Helmholtz Centre for Infection Research
Press and Communications
Inhoffenstr. 7
D-38124 Braunschweig
Germany

Phone: +49 531 6181-1404

Originalpublikation:

Philipp Le, Elena Kunold, Robert Macsics, Katharina Rox, Megan C. Jennings, Ilke Ugur, Maria Reinecke, Diego Chaves-Moreno, Mathias W. Hackl, Christian Fetzer, Franziska A. M. Mandl, Johannes Lehmann, Vadim S. Korotkov, Stephan M. Hacker, Bernhard Kuster, Iris Antes, Dietmar H. Pieper, Manfred Rohde, William M. Wuest, Eva Medina, Stephan A. Sieber: Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nature Chemistry 2019, doi: 10.1038/s41557-019-0378-7

Susanne Thiele | Helmholtz-Zentrum für Infektionsforschung
Further information:
http://www.helmholtz-hzi.de

More articles from Life Sciences:

nachricht A new 'cool' blue
17.01.2020 | American Chemical Society

nachricht Neuromuscular organoid: It’s contracting!
17.01.2020 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Miniature double glazing: Material developed which is heat-insulating and heat-conducting at the same time

Styrofoam or copper - both materials have very different properties with regard to their ability to conduct heat. Scientists at the Max Planck Institute for Polymer Research (MPI-P) in Mainz and the University of Bayreuth have now jointly developed and characterized a novel, extremely thin and transparent material that has different thermal conduction properties depending on the direction. While it can conduct heat extremely well in one direction, it shows good thermal insulation in the other direction.

Thermal insulation and thermal conduction play a crucial role in our everyday lives - from computer processors, where it is important to dissipate heat as...

Im Focus: Fraunhofer IAF establishes an application laboratory for quantum sensors

In order to advance the transfer of research developments from the field of quantum sensor technology into industrial applications, an application laboratory is being established at Fraunhofer IAF. This will enable interested companies and especially regional SMEs and start-ups to evaluate the innovation potential of quantum sensors for their specific requirements. Both the state of Baden-Württemberg and the Fraunhofer-Gesellschaft are supporting the four-year project with one million euros each.

The application laboratory is being set up as part of the Fraunhofer lighthouse project »QMag«, short for quantum magnetometry. In this project, researchers...

Im Focus: How Cells Assemble Their Skeleton

Researchers study the formation of microtubules

Microtubules, filamentous structures within the cell, are required for many important processes, including cell division and intracellular transport. A...

Im Focus: World Premiere in Zurich: Machine keeps human livers alive for one week outside of the body

Researchers from the University Hospital Zurich, ETH Zurich, Wyss Zurich and the University of Zurich have developed a machine that repairs injured human livers and keep them alive outside the body for one week. This breakthrough may increase the number of available organs for transplantation saving many lives of patients with severe liver diseases or cancer.

Until now, livers could be stored safely outside the body for only a few hours. With the novel perfusion technology, livers - and even injured livers - can now...

Im Focus: SuperTIGER on its second prowl -- 130,000 feet above Antarctica

A balloon-borne scientific instrument designed to study the origin of cosmic rays is taking its second turn high above the continent of Antarctica three and a half weeks after its launch.

SuperTIGER (Super Trans-Iron Galactic Element Recorder) is designed to measure the rare, heavy elements in cosmic rays that hold clues about their origins...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

„Advanced Battery Power“- Conference, Contributions are welcome!

07.01.2020 | Event News

 
Latest News

A new 'cool' blue

17.01.2020 | Life Sciences

EU-project SONAR: Better batteries for electricity from renewable energy sources

17.01.2020 | Power and Electrical Engineering

Neuromuscular organoid: It’s contracting!

17.01.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>